References
- Penfold PL, Gyory JF, Hunyor AB, Billson FA. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust. N. Z. J. Ophthalmol.23, 293–298 (1995).
- Roth DB, Flynn HW Jr. Distinguishing between infectious and noninfectious endophthalmitis after intravitreal triamcinolone injection. Am. J. Ophthalmol.146, 346–347 (2008).
- Jonisch J, Lai JC, Deramo VA et al. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br. J. Ophthalmol.92, 1051–1054 (2008).
- Lorenzo Carrero J, Gonzalez Barcia M, Perez Flores I. Sterile endophthalmitis after benzyl alcohol filtered triamcinolone acetonide injection. Arch. Ophthalmol.126, 142–143 (2008).
- Jonas JB, Kreissig I, Spandau UH et al. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide. Am. J. Ophthalmol.141, 579–580 (2006).
- Criswell MH, Hu W, Yuan P et al. Differences in the intravitreal dosage of triamcinolone acetonide can elicit inhibition or paradoxical augmentation of choroidal neovascularization (CNV) in rat. Invest. Ophthalmol. Vis. Sci.48, ARVO E-Abstract 3394 (2007).
- Rodriguez-Coleman H, Yuan P, Kim H et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch. Ophthalmol.122, 1085–1086 (2004).
- Maia M, Farah ME, Belfort RN et al. Effects of intravitreal triamcinolone acetonide injection with and without preservatives. Br. J. Ophthalmol.91, 1122–1124 (2007).
- Dyer D, Callanan D, Bochow T et al. Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (Triesence [triamcinolone acetonide injectable suspension] 40 mg/ml) for visualization during pars plana vitrectomy. Retina29, 38–45 (2009).
- Kim H, Csaky KG, Gravlin L et al. Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. Retina26, 523–530 (2006).
- Metrikin DC, Wilson CA, Berkowitz BA et al. Measurement of blood–retinal barrier breakdown in endotoxin-induced endophthalmitis. Invest. Ophthalmol. Vis Sci36, 1361–1370 (1995).
- Kumagai N, Fukuda K, Fujitsu Y et al. Lipopolysaccharide-induced expression of intercellular adhesion molecule-1 and chemokines in cultured human corneal fibroblasts. Invest. Ophthalmol. Vis. Sci.46, 114–120 (2005).
- Mamalis N, Edelhauser HF, Dawson DG et al. Toxic anterior segment syndrome. J. Cataract Refract. Surg.32, 324–333 (2006).
- Nair B. Final report on the safety assessment of benzyl alcohol, benzoic acid, and sodium benzoate. Int. J. Toxicol.20(Suppl. 3), 23–50 (2001).
- Hiller JL, Benda GI, Rahatzad M et al. Benzyl alcohol toxicity: impact on mortality and intraventricular hemorrhage among very low birth weight infants. Pediatrics77, 500–506 (1986).
- Kai W, Yanrong J, Xiaoxin L. Vehicle of triamcinolone acetonide is associated with retinal toxicity and transient increase of lens density. Graefes Arch. Clin. Exp. Ophthalmol.244, 1152–1159 (2006).
- Cebula TA, El-Hage AN, Ferrans VJ. Toxic interactions of benzyl alcohol with bacterial endotoxin. Infect. Immun.44, 91–96 (1984).
- Morrison VL, Koh HJ, Cheng L et al. Intravitreal toxicity of the Kenalog vehicle (benzyl alcohol) in rabbits. Retina26, 339–344 (2006).
- Cannon GJ, Swanson JA. The macrophage capacity for phagocytosis. J. Cell Sci.101(Pt 4), 907–913 (1992).
- McCarty DJ, Hogan JM. Inflammatory reaction after intrasynovial injection of microcrystalline adrenocorticosteroid esters. Arthritis Rheum.7, 359–367 (1964).
- Roth DB, Prenner JL, Krajnky O. Incidence of noninfectious endophthalmitis after intravitreal injection of preservative-free triamcinolone acetonide. Retin. Cases Brief Rep.2, 247–249 (2008).
- Krah JL, Krimmel D, Dodwell D. Sterile endophthalmitis secondary to intravitreal Triesence (triamcinolone acentonide). Invest. Ophthalmol. Vis. Sci.50, E-Abstract 3565 (2009).
- Bhavsar AR, Ip MS, Glassman AR. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am. J. Ophthalmol.144, 454–456 (2007).
- Moshfeghi AA, Nugent AK, Nomoto H et al. Triamcinolone acetonide preparations: impact of crystal size on in vitro behavior. Retina29, 689–698 (2009).
Website
- US FDA. FDA-requested recall – Cytosol Laboratories, Inc. product contains dangerous levels of endotoxin. 13 February 2006. www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150520.htm